Ticker > Company >

Nectar Lifesciences share price

Nectar Lifesciences Ltd.

NSE: NECLIFE BSE: 532649 SECTOR: Pharmaceuticals & Drugs  60.34 K   79   23

13.77
+0.27 (2.00%)
BSE: 16 Oct 04:01 PM

Price Summary

Today's High

₹ 13.77

Today's Low

₹ 13.51

52 Week High

₹ 44.9

52 Week Low

₹ 13.25

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

308.81 Cr.

Enterprise Value

871.61 Cr.

No. of Shares

22.43 Cr.

P/E

0

P/B

0.35

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  39.81

CASH

19.22 Cr.

DEBT

582.02 Cr.

Promoter Holding

44.91 %

EPS (TTM)

₹  -8.02

Sales Growth

-0.84%

ROE

-11.23 %

ROCE

-4.68%

Profit Growth

-2372.71 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-0.84%
3 Year0.03%
5 Year-6.71%

Profit Growth

1 Year-2372.71%
3 Year-264.97%
5 Year-229.41%

ROE%

1 Year-11.23%
3 Year-4.28%
5 Year-3.43%

ROCE %

1 Year-4.68%
3 Year1.53%
5 Year2.36%

Debt/Equity

0.6087

Price to Cash Flow

1.82

Interest Cover Ratio

-0.8875

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2025 44.91 98.77
Jun 2025 44.53 99.60
Mar 2025 44.53 99.60
Dec 2024 44.53 99.60
Sep 2024 55.80 100.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 88.6849 days.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 72.1387180507772.

 Limitations

  • The company has shown a poor profit growth of -264.97117258327% for the Past 3 years.
  • The company has shown a poor revenue growth of 0.034814840493036% for the Past 3 years.
  • Company has a poor ROE of -4.2815% over the past 3 years.
  • Company has a poor ROCE of 1.5263% over the past 3 years
  • Company has low Interest coverage ratio of -0.8875.
  • Promoter pledging is high as 98.77%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 359.3 428.1 454.98 430.7 280.67
Total Expenditure 319.5 384.77 410.27 585 342.57
Operating Profit 39.8 43.33 44.71 -154.3 -61.9
Other Income 0.55 0.69 0.57 0.08 0.35
Interest 19.98 19.81 17.12 17.67 18.7
Depreciation 15.46 15.55 15.61 15.77 16.52
Exceptional Items 0 0 0 0 0
Profit Before Tax 4.92 8.67 12.55 -187.67 -96.76
Tax 1.95 3.07 4.71 -57.58 -33.52
Profit After Tax 2.97 5.6 7.84 -130.09 -63.23
Adjusted EPS (Rs) 0.13 0.25 0.35 -5.8 -2.82

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 1541.82 1668.23 1523.67 1684.09 1669.97
Total Expenditure 1440.26 1509.42 1468.95 1532.53 1699.53
Operating Profit 101.57 158.81 54.72 151.56 -29.56
Other Income 11.38 11.32 53.06 26.81 15.99
Interest 112.03 78.81 89.35 99.37 85.58
Depreciation 60.25 56.97 59.12 60.72 62.39
Exceptional Items -25.32 0 0 0 0
Profit Before Tax -84.65 34.35 -40.69 18.28 -161.53
Tax -11.5 9.03 -18.24 13.27 -47.85
Net Profit -72.75 25.32 -22.46 5 -113.68
Adjusted EPS (Rs.) -3.26 1.13 -1 0.22 -5.07

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 22.43 22.43 22.43 22.43 22.43
Total Reserves 1038.31 1064.44 1042.17 1046.83 933.69
Borrowings 128.24 291.08 226.47 140.31 60.13
Other N/C liabilities -1.45 5.59 -13.35 1.21 -45.59
Current liabilities 1187.39 1003.75 890.93 972.82 1021.54
Total Liabilities 2374.91 2387.27 2168.64 2183.58 1992.19
Assets
Net Block 771.89 723.1 661.97 642.71 633.11
Capital WIP 98.63 85.1 77.78 65.75 56.73
Intangible WIP 0 0 0 0 0
Investments 0.57 0.57 0.24 0.24 0.24
Loans & Advances 14.67 12.26 10.93 12.62 13.41
Other N/C Assets 251.59 212.5 186.54 178.44 51.11
Current Assets 1237.57 1353.75 1231.18 1283.83 1237.59
Total Assets 2374.91 2387.27 2168.64 2183.58 1992.19
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations -84.65 34.35 -40.69 18.28 -161.53
Adjustment 148.28 125.44 97.08 137.55 139.02
Changes in Assets & Liabilities -38.69 -64.75 76.98 68.87 191.95
Tax Paid -3.61 0 0 0 0
Operating Cash Flow 21.33 95.04 133.37 224.69 169.44
Investing Cash Flow -28.62 16.64 52.03 -17.03 -41.93
Financing Cash Flow 11.49 -119.38 -185.57 -205.44 -128.09
Net Cash Flow 4.2 -7.7 -0.17 2.23 -0.58

Corporate Actions

Investors Details

PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
promoters 55.80 44.53 44.53 44.53 44.91
raman goyal - - 0.18 0.18 0.55
sanjiv (huf) - karta sanj... - - - 19.45 19.45
sanjiv goyal 31.33 24.90 24.90 24.90 24.90
sanjiv (huf) 24.47 19.45 19.45 - -
raman goyal - 0.18 - - -
PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
investors 44.20 55.47 55.47 55.47 55.09
jaideep sampat 1.81 2.07 1.83 2.00 1.78
anita jaideep sampat - - 1.35 1.02 -
investor education and pr... - - - 0.06 -
investor education and pr... 0.05 0.06 0.06 - -
malti narendra sampat - - 1.02 - -
ingain traders, llc 1.34 - - - -
sahastraa advisors privat... 1.21 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q3FY25
Presentation Q3FY25

Company News

Nectar Lifesciences informs about newspaper publication 29 Aug, 12:45 PM Nectar Lifesciences - Quaterly Results 14 Aug, 4:52 PM Nectar Lifesciences - Quaterly Results 14 Aug, 4:52 PM Nectar Lifesciences submits board meeting intimation 11 Aug, 2:59 PM Nectar Lifesciences Gujarat Narmada Valley Fertilizers & Chemicals informs about newspaper publication 24 Jul, 4:15 PM Nectar Lifesciences informs about newspaper publication 9 Jul, 12:19 PM Nectar Lifesciences to sell API business and formulations for Rs 1,270 crore 8 Jul, 9:28 AM Nectar Lifesciences informs about press release 8 Jul, 9:24 AM Nectar Lifesciences - Quaterly Results 7 Jul, 11:26 PM Nectar Lifesciences - Quaterly Results 7 Jul, 11:26 PM Nectar Lifesciences informs about closure of trading window 27 Jun, 11:56 AM Nectar Lifesciences informs about disclosures 11 Jun, 12:35 PM Nectar Lifesciences informs about certificate 5 Apr, 3:05 PM Nectar Lifescience informs about disclosures 4 Apr, 4:57 PM Nectar Lifesciences receives 7 observations for API manufacturing facility 11 Mar, 11:30 AM Nectar Lifesciences informs about resignation of CS cum CO 28 Feb, 4:28 PM Nectar Lifesciences - Quaterly Results 31 Jan, 5:17 PM Nectar Lifesciences - Quaterly Results 31 Jan, 5:17 PM Nectar Lifesciences - Quaterly Results 31 Jan, 5:17 PM Nectar Lifesciences informs about disclosure 10 Jan, 12:48 PM Nectar Lifesciences informs about closure of trading window 26 Dec, 3:04 PM Nectar Lifesciences informs about disclosure 13 Dec, 2:19 PM Nectar Lifesciences informs about disclosure 13 Dec, 2:18 PM Nectar Lifesciences informs about disclosure 21 Nov, 1:41 PM Nectar Lifesciences informs about disclosure 21 Nov, 1:40 PM Nectar Lifesciences informs about disclosure 21 Nov, 1:38 PM Nectar Lifesciences informs about disclosure 21 Nov, 1:37 PM Nectar Lifesciences informs about disclosures 4 Oct, 5:01 PM Nectar Lifesciences informs about disclosures 4 Oct, 2:45 PM Nectar Lifesciences informs about AGM minutes 28 Sep, 3:40 PM Nectar Lifesciences informs about trading window closure 26 Sep, 5:28 PM Nectar Lifesciences informs about press release 20 Aug, 2:00 PM Nectar Lifesciences - Quaterly Results 14 Aug, 1:26 PM Nectar Lifesciences informs about compliance certificate 4 Jul, 1:26 PM Nectar Lifesciences informs about newspaper publication 16 May, 12:14 PM Nectar Lifesciences - Quaterly Results 15 May, 2:35 PM Nectar Lifesciences - Quaterly Results 15 May, 2:35 PM Nectar Lifesciences - Quaterly Results 15 May, 2:35 PM Nectar Lifesciences informs about newspaper publication 15 Feb, 12:07 PM Nectar Lifesciences - Quaterly Results 14 Feb, 2:20 PM Nectar Lifesciences - Quaterly Results 14 Feb, 2:20 PM Nectar Lifesciences informs about trading window closure 28 Dec, 3:30 PM Nectar Lifesciences - Quaterly Results 14 Aug, 1:28 PM Nectar Lifesciences - Quaterly Results 14 Aug, 1:28 PM Nectar Lifesciences submits board meeting intimation 5 Aug, 2:46 PM Nectar Lifesciences - Quaterly Results 26 May, 1:38 PM Nectar Lifesciences - Quaterly Results 14 Feb, 2:10 PM Nectar Lifesciences informs about updates 10 Feb, 3:06 PM Nectar Lifesciences - Quaterly Results 14 Nov, 6:25 PM Nectar Lifesciences informs about proceedings of AGM 21 Sep, 4:43 PM

Nectar Lifesciences Stock Price Analysis and Quick Research Report. Is Nectar Lifesciences an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Nectar Lifesciences. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Nectar Lifesciences has a PE ratio of -1.71422872174639 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Nectar Lifesciences has ROA of -5.4448% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Nectar Lifesciences has a Current ratio of 1.2115.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Nectar Lifesciences has a ROE of -11.2257%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Nectar Lifesciences has a Debt to Equity ratio of 0.6087 which means that the company has low proportion of debt in its capital.

  • Sales growth: Nectar Lifesciences has reported revenue growth of -0.838% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Nectar Lifesciences for the current financial year is -1.77002755731526%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Nectar Lifesciences is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Nectar Lifesciences is Rs -8.0211. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Nectar Lifesciences in Ticker for free. Also, one can get the intrinsic value of Nectar Lifesciences by using Valuation Calculators, which are available with a Finology ONE subscription. 

Nectar Lifesciences FAQs

Q1. What is Nectar Lifesciences share price today?
Ans: The current share price of Nectar Lifesciences is Rs 13.75.

Q2. What is the market capitalisation of Nectar Lifesciences?
Ans: Nectar Lifesciences has a market capitalisation of Rs 308.35883375 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Nectar Lifesciences?
Ans: The PE ratio of Nectar Lifesciences is -1.71422872174639 and the P/B ratio of Nectar Lifesciences is 0.345352435299791, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Nectar Lifesciences share?
Ans: The 52-week high share price of Nectar Lifesciences is Rs 44.41, and the 52-week low share price of Nectar Lifesciences is Rs 13.05.

Q5. Does Nectar Lifesciences pay dividends?
Ans: Currently, Nectar Lifesciences does not pay dividends. Dividend yield of Nectar Lifesciences is around 0%.

Q6. What are the face value and book value of Nectar Lifesciences shares?
Ans: The face value of Nectar Lifesciences shares is Rs 1, while the book value per share of Nectar Lifesciences is around Rs 39.8144. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Nectar Lifesciences?
Ans: Nectar Lifesciences has a total debt of Rs 582.022 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Nectar Lifesciences?
Ans: The ROE of Nectar Lifesciences is -11.2257% and ROCE of Nectar Lifesciences is -4.6843%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Nectar Lifesciences a good buy for the long term?
Ans: The Nectar Lifesciences long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Nectar Lifesciences undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Nectar Lifesciences appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Nectar Lifesciences’s financials?
Ans: You can review Nectar Lifesciences’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Nectar Lifesciences
X